ReviewJournal of oral biology and craniofacial research
Recent advances in tumor targeted polymeric nanoparticles for HNC treatment: Enhancing therapeutic efficacy via engineered and biocompatible drug delivery systems.
Review in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.International journal of pharmaceutics: X · 2026Review
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Reprogramming dendritic cells to overcome tumor-mediated immune suppression.Frontiers in immunology · 2026Review
- Targeted nanoparticle-mediated Co-delivery of IFITM3 KO and ponatinib reverses TKI resistance in chronic myeloid leukemia.Frontiers in pharmacology · 2026Article
- Nanobiotic-Enhanced Probiotics for Targeted Gut Delivery: Mechanisms, Therapeutic Applications, and Translational Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck cancer (HNC) represents a heterogeneous group of malignancies with high global incidence and mortality rates. Traditional treatments for advanced HNC, such as combined radiotherapy and chemotherapy, often lead to debilitating long-term side effects that significantly affect patients quality of life. In response to these limitations, tumor-targeted polymer-based nanoparticles have emerged as a promising strategy to improve therapeutic efficacy while minimizing adverse effects. Polymeric nanoparticles comprised of natural or synthetic polymers and sized between 10 and 1000 nm have several benefits, including biocompatibility, adaptable drug release patterns, and the capacity to improve the solubility and stability of medicinal compounds. These nanoparticles can be engineered to target medications to tumor sites specifically, lowering systemic toxicity and enhancing treatment results. This review focuses on recent advances in the targeted therapy of HNC using polymeric nanoparticles such as chitosan, alginate, cyclodextrin, poly (lactic acid), poly (caprolactone), poly (ethylene glycol), dendrimers, and micelles. The emphasis is on their mechanisms, advantages, and potential to transform present HNC treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.